This roundtable series reviews immunotherapy in patients with unresectable hepatocellular carcinoma as first-line treatment, as discussed by key opinion leaders and participants at virtual live events.
The Expansion of Treatment in the Firstline Setting of HCC
Richard Kim, MD, walks through options in the frontline setting for patients with advanced staged hepatocellular carcinoma and how newer treatments have impacted this patient population.
Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCC
Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.
2 Clarke Drive Cranbury, NJ 08512